Samsung Seoul Hospital and Kangbuk Samsung Hospital are collaborating to develop reverse translational research-based AI software. Daewoong Pharmaceutical announced on the 17th that it has been selected as a core research partner in the government’s AI drug development platform project. The project, led by the Ministry of Health and Welfare, focuses on developing preclinical and clinical models for the “2025 K-AI New Drug Development” initiative.
The project’s goal is to establish an ecosystem that applies AI throughout the entire drug development cycle, from preclinical to clinical stages. Daewoong Pharmaceutical, in collaboration with Samsung Seoul Hospital and Kangbuk Samsung Hospital, will develop AI software based on reverse translational research.
Reverse translational research involves using clinical data to inform and enhance preclinical study designs. By integrating AI models, this approach aims to reduce trial and error in the development process and increase the likelihood of success. Over the next four years, Daewoong Pharmaceutical will provide non-clinical data for oncology and metabolic diseases and participate in AI software validation using research data from its new drug center.
The company plans to enhance research and development efficiency by advancing AI-based animal testing models and acquiring clinical prediction technology based on non-clinical data. Additionally, it aims to expand its AI models, initially focused on oncology and metabolic diseases, to cover a broader range of conditions, thereby accelerating the expansion of its pipeline.
Sung-soo Park, CEO of Daewoong Pharmaceutical, stated, “By participating in the model development directly in the field, we will elevate our R&D capabilities to a new level,” and he expressed his commitment to contributing to the establishment of an AI-based innovative new drug ecosystem.